All patients will have blood tests, examinations , and CT scans of the chest/abdomen/pelvis or other imagin g studies as described in the monitoring schedule. Becaus e this is a first- in-human study, nothing is known directly about the clinical benefit or risk of this vaccine. However, we have previously tested a vaccine targeting the same antigen (brachyury ) with no significant toxicity. Additionally, the LTIB has a l ong history with viral - vector vaccines, including vaccinia, from which MVA is derived. MVA is considered to be a safer alternative to vaccinia. The toxicity profile of vaccinia as a vector for therapeutic cancer vaccines has been excellent.46 Given preclinical data, the side effects are expected to be minor and reversible. Efforts to minimize risk include subcutaneous administration, close clinical monitoring after dose administration, and treatment of any side effects.